The race between two drug makers to market a generic version of a blockbuster blood thinner has grown so intense that one company hired the Kroll detective and security firm, prompting an inquiry by two key senators, The Wall Street Journal reports. Both Amphastar Pharmaceuticals and Momenta Pharmaceuticals hired high-profile Washington lobbyists as they await FDA approval for generic versions ...

EXCERPTED FROM ABOVE LINK: ..Executives inside pharmaceutical giant AstraZeneca faced a high-stakes dilemma.On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look spectacular.On the other, some worried that his research findings might be too good to be true.As Reinstein ...

Executives inside pharmaceutical giant AstraZeneca faced a high-stakes dilemma. On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look spectacular. On the other, some worried that his research findings might be too good to be true.

by Christina Jewett, ProPublica, and Sam Roe, Chicago Tribune - This story was co-published with the Chicago Tribune. Executives inside pharmaceutical giant AstraZeneca faced a high-stakes dilemma. On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look ...

This story was co-published with the Chicago Tribune. Executives inside pharmaceutical giant AstraZeneca faced a high-stakes dilemma. On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look spectacular. On the other, some worried that his research findings might be too ...

One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to ... seems that just like branded pharmas, Mylan benefited from cost cuts. Still, the world's No. 3 generic drugmaker raised its full-year outlook and said it believes it can continue its current momentum into 2010. Continue reading ...